What's Happening?
Precision BioSciences, a gene editing company, is set to host an investor webcast to discuss new clinical and biopsy data from its ongoing ELIMINATE-B trial. This trial evaluates PBGENE-HBV, a gene editing therapy designed to potentially cure chronic
hepatitis B by eliminating cccDNA, the root cause of the infection. The webcast will feature company management and hepatitis B experts, providing insights into the trial's progress and the therapy's potential. PBGENE-HBV is the first gene editing program targeting cccDNA to enter clinical trials and has received Fast Track designation from the FDA.
Why It's Important?
Chronic hepatitis B is a significant global health challenge, with existing treatments often failing to provide a cure. PBGENE-HBV's approach to eliminating cccDNA could offer a groundbreaking solution, potentially leading to a sustained viral cure. The therapy's development is crucial for addressing the unmet needs of patients with chronic hepatitis B, offering hope for a more effective and lasting treatment. The webcast will provide stakeholders with valuable updates on the therapy's clinical progress and its implications for the future of hepatitis B treatment.
What's Next?
The investor webcast is scheduled for May 27, 2026, and will be available for replay on Precision BioSciences' website. The company will continue to advance the ELIMINATE-B trial, with further data releases expected as the study progresses. The outcomes of this trial could influence regulatory pathways and future clinical strategies for gene editing therapies targeting infectious diseases.
